Of all the FDA-approved weight loss medications now available, Zepbound (tirzepatide) stands out for both the scale and consistency of its clinical results. Developed by Eli Lilly, Zepbound is a dual agonist that activates both GLP-1 and GIP receptors—two complementary metabolic pathways that together produce significantly greater appetite reduction, blood sugar control, and sustained weight loss than single-receptor therapies can achieve alone.

The Science Behind Zepbound’s Dual Mechanism

The GLP-1 (glucagon-like peptide-1) pathway signals fullness to the brain, slows gastric emptying, and stimulates appropriate post-meal insulin release. The GIP (glucose-dependent insulinotropic polypeptide) pathway enhances insulin sensitivity, contributes an additional layer of appetite regulation, and influences energy metabolism in ways that complement GLP-1 activity.

Together, these mechanisms produce a more powerful and sustained reduction in hunger and caloric intake than either pathway delivers individually. Clinical trials of tirzepatide have reported average body weight reductions of 15–22% in some patient groups—outcomes that approach those seen with certain surgical interventions and significantly exceed those of earlier GLP-1 medications.

Who Is a Candidate for Zepbound

Zepbound is FDA-approved for adults with a BMI of 30 or above, or 27 or above with at least one weight-related health condition such as Type 2 diabetes, hypertension, or dyslipidaemia. Beyond those criteria, clinical suitability depends on a thorough evaluation of health history, existing medications, and metabolic profile. Patients managing multiple metabolic conditions simultaneously, those who have not achieved adequate results on earlier GLP-1 therapies, and those seeking the most clinically advanced pharmacological option available are often strong candidates.

What to Expect During Treatment

Zepbound is administered as a once-weekly subcutaneous injection, beginning at a low dose—typically 2.5 mg—and increasing gradually over several months to a maintenance dose. This titration schedule is deliberately structured to allow the body to adjust and to minimise early digestive side effects such as nausea, which the majority of patients find manageable and temporary.

Results typically begin to emerge in the first four to eight weeks as appetite decreases and portions naturally reduce. Progressive weight loss builds steadily over the following months, alongside improvements in blood glucose, blood pressure, and lipid levels that are themselves clinically meaningful for long-term health risk reduction.

Zepbound Under the Care of Adonis Saremi, MD

For patients in San Diego seeking Zepbound for weight loss with a physician who holds triple board certification in Obesity Medicine, Internal Medicine, and Clinical Informatics, Adonis Saremi, MD offers a fully personalised, concierge-delivered programme. Every Zepbound prescription follows a comprehensive clinical evaluation, and ongoing care is provided through telemedicine, in-office appointments for Executive members, and VIP Preview (opens in a new tab)in-home visits. The direct, continuous physician relationship at the heart of Adonis Saremi, MD’s practice ensures that Zepbound therapy is managed with the clinical depth and personalised attention that produces genuinely lasting results.